ViewRay Receives Chinese Regulatory Approval for its MRIdian System

Brings Benefits of MRI-Guided Radiation Therapy to Large and Growing Chinese Market

CLEVELAND, Sept. 9, 2016 /PRNewswire/ —  ViewRay, Inc. (Nasdaq: VRAY) announced today that the company has received China Food and Drug Administration (CFDA) approval for its MRIdian System, the world’s first and only clinical MRI-guided radiation therapy system.

The MRIdian system is a unique medical instrument that integrates full-time MR imaging, cobalt radiation delivery, and intelligent software automation to treat cancers throughout the body. Using the MRIdian system, clinicians can see soft tissue, and visualize and adjust the dose — all in real time, on live anatomy. With MRIdian this is done without exposing the patient to the additional ionizing radiation that is common with other imaging modalities.

“China is one of the largest markets for medical devices in the world, so securing CFDA approval is an important step in our growth strategy,” said Chris A. Raanes, president and chief executive officer ofViewRay. “Given its population and rising cancer incidence, we believe MRI-guided radiation therapy will be an important cancer fighting tool for doctors and their patients throughout China.”

ViewRay is represented in China by Cowealth Medical Holding Co.

“We’re pleased to partner with ViewRay to bring the benefits of MRIdian to China,” said Duane Lee, president and chief executive officer of Cowealth.  “We believe MRI-guided radiation therapy is an essential advancement in radiation oncology and look forward to helping expand access to this vital treatment option.”